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Abstract
Background: After menopause, 10–20% of all women have nearly intolerable hot flushes. Long
term use of hormone replacement therapy involves a health risk, and many women seek alternative
strategies to relieve climacteric complaints. Acupuncture is one of the most frequently used
complementary therapies in Norway. We designed a study to evaluate whether Traditional
Chinese Medicine acupuncture-care together with self-care is more effective than self-care alone
to relieve climacteric complaints.
Methods/Design: The study is a multi-centre pragmatic randomised controlled trial with two
parallel arms. Participants are postmenopausal women who document ≥7 flushes/24 hours and who
are not using hormone replacement therapy or other medication that may influence flushes.
According to power calculations 200 women are needed to detect a 50% reduction in flushes, and
altogether 286 women will be recruited to allow for a 30% dropout rate.
The treatment group receives 10 sessions of Traditional Chinese Medicine acupuncture-care and
self-care; the control group will engage in self-care only. A team of experienced Traditional Chinese
Medicine acupuncturists give acupuncture treatments.
Discussion:  The study tests acupuncture as a complete treatment package including the
therapeutic relationship and expectation. The intervention period lasts for 12 weeks, with follow
up at 6 and 12 months. Primary endpoint is change in daily hot flush frequency in the two groups
from baseline to 12 weeks; secondary endpoint is health related quality of life, assessed by the
Women's Health Questionnaire. We also collect data on Traditional Chinese Medicine diagnoses,
and we examine treatment experiences using a qualitative approach. Finally we measure biological
variables, to examine potential mechanisms for the effect of acupuncture. The study is funded by
The Research Council of Norway.
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Background
After menopause, almost two thirds of women experience
hot flushes. One third have symptoms persisting up to
five years after natural menopause, and 10–20% find
symptoms very distressing [1]. Hormone replacement
therapy (HRT) is considered the most effective treatment
for hot flushes [2]. However, HRT has other biological
effects: it prevents fractures and cancer of the colon [3],
but increases the risk of breast cancer [4] and thrombo-
embolic disease [5]. Based on these data, the Norwegian
Medicines Agency revised the guidelines for prescribing
HRT in 2003 [6]. Indications are now only hot flushes and
urogenital symptoms. HRT should be used for a short
time period, in the lowest possible dose, and other strate-
gies should be considered. The reports of adverse events
generated considerable public interest in Norway, and
sales figures for systemic HRT have decreased by 45 %
since 2001 [7]. Moreover, a Scandinavian study con-
ducted among women treated for breast cancer was termi-
nated when the interim analysis showed that HRT was
associated with an increased risk for relapse of the disease
[8]. A Norwegian cohort study showed that HRT formula-
tions used in Norway are also associated with an increased
risk of breast cancer [9]. The data received considerable
public attention and we suppose that they enhanced Nor-
wegian women's interest in low risk strategies to relieve
their climacteric complaints.
A large body of data already shows that HRT effectively
relieves hot flush activity (frequency and severity) by
approximately 80% [2]. Estrogen placebo interventions
reduce hot flush activity by 20–30% [10]. Selective serot-
onin reuptake inhibitors (SSRIs) and selective noradrena-
line reuptake inhibitors (SNRIs) reduce the number of hot
flushes by 50–60% in the short term in some studies [11].
On this basis it has been advocated that clinically relevant
interventions must have the ability to reduce hot flush
activity by 50% or more [10].
Women may explore other approaches to manage their
menopausal symptoms. These include phyto-estrogens
such as soy, herbal remedies such as black cohosh and red
clover, or vitamin E. There is a lack of good evidence of
their effectiveness, and lack of knowledge of drug interac-
tions and of long-term safety [1]. Commonly recom-
mended lifestyle changes include stress reduction,
increased fruit and vegetable intake, reduced caffeine and
alcohol intake, smoking cessation, and increased physical
exercise. The evidence for these is anecdotal, supported in
some cases by epidemiological studies but not by inter-
vention trials [12].
Acupuncture is one of the most frequently used comple-
mentary therapies in Norway [13], and is considered safe
in the hands of competent practitioners [14]. One small
randomised trial (n = 24) conducted in a Swedish univer-
sity clinic showed that hot flushes decreased by 50%
among women who received standardized electroacu-
puncture [15]. A further study (n = 30) by the same group
found a trend in favour of acupuncture compared with
sham acupuncture for climacteric symptoms [16]. In a
small crossover study (n = 10) in hypertensive postmeno-
pausal women, acupuncture was associated with a signifi-
cant reduction in 'complaints' though not in blood
pressure [17]. An uncontrolled study in 11 participants
found a mean reduction in flush score from 4.2 to 1.9
[18]. A small RCT (n = 16) found genuine acupuncture
more effective than sham-acupuncture, with a 76% reduc-
tion in flushes [19]. An unpublished Norwegian case
series (n = 18) suggests that individualized Traditional
Chinese Medicine (TCM) acupuncture can reduce hot
flushes by 77%. The current data are insufficient to make
recommendations regarding acupuncture treatment for
hot flushes, but sufficient to justify further research.
Two studies of acupuncture for hot flushes published
since the development of this protocol yielded conflicting
results: one study of 103 participants found no effect on
daily flush frequency [20], whereas a second study of 29
participants found a reduction in severity but not fre-
quency of nocturnal flushes [21].
There is common agreement among acupuncturists that a
minimum of six treatment sessions are necessary to evalu-
ate treatment effect, and as many as eight to ten sessions
are necessary to establish a maximum effect [22]. Contin-
uation of the effect may require repeated, but less fre-
quent, treatments. If symptoms relapse, as little as two to
three treatments can be sufficient to trigger the treatment
effect again. An acupuncture session usually costs NOK
300, and accordingly a typical series of treatments costs
NOK 3000.
In Norway, most acupuncture practitioners use the TCM
approach, and about 500 practitioners belong to the pro-
fessional organisation, NAFO. A woman who seeks a TCM
acupuncture practitioner for hot flushes chooses a treat-
ment strategy rather than a single intervention. The prac-
titioner will most likely focus on climacteric complaints
and general well being rather than hot flush activity alone.
Treatment involves a comprehensive TCM diagnostic pro-
cedure and general life-style advice in addition to individ-
ualized acupuncture treatment. Acupuncturists generally
consider that these elements interact intentionally with
each other during treatment and constitute a treatment
package, i.e. "acupuncture-care". If the elements are sepa-
rated, the treatment will not reflect what TCM acupunctur-
ists consider relevant and good quality acupuncture for a
given condition.BMC Complementary and Alternative Medicine 2007, 7:6 http://www.biomedcentral.com/1472-6882/7/6
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Methods/design
The objective of the study is to address a pragmatic ques-
tion, to compare the effectiveness of two low risk strate-
gies to relieve climacteric complaints in postmenopausal
women who seek alternatives to HRT: is individualized
TCM acupuncture-care together with self-care more effec-
tive at reducing the frequency and severity of hot flushes
compared with self-care alone. The study will test acu-
puncture as a complete treatment package, i.e. including
the therapeutic relationship and expectation, and address
the important question of the overall effect of acupunc-
ture-care, which is highly relevant to both postmenopau-
sal women and their health care providers. The
limitations of other possible control groups are discussed
below. The changes that are likely to be experienced by
women undergoing acupuncture in this study will not be
fully captured by the quantitative measures used, and
therefore the study team will collaborate with other inves-
tigators who wish to explore these qualitatively. If the
study shows that acupuncture-care has a clinically relevant
effect on climacteric complaints, the research group will
proceed further and apply for funding to perform a pla-
cebo-controlled trial to determine the importance of nee-
dle insertion in the overall effect of acupuncture
treatment. In addition, a positive result will justify a study
of the effect of acupuncture in other groups of patients
such as women with hot flushes induced by tamoxifen
and men undergoing treatment for prostate cancer.
A sub-study is conducted in 70 women who participate in
the Tromsø-arm of the study, to investigate effects of acu-
puncture-care on biological variables. Evaluations take
place at baseline and after 12 weeks. It is hypothesized
that acupuncture reduces hot flushes by increasing β-
endorphin activity in the hypothalamus [15]. Calcitonin
gene-related peptide (CGRP) is a potent vasodilator, and
may be a proxy for β-endorphin activity [15]. Plasma con-
centration of CGRP and neuropeptide Y (NPY) increases
during a hot flush [23], and the urine excretion of CGRP
is reduced parallel to the reduction of hot flushes after
acupuncture treatment [15]. The urine excretion of CGRP
and NPY will be measured.
Acupuncture can modulate autonomic nerve system activ-
ity [24], and central sympathetic activity is considered to
influence hot flush activity [25]. Autonomic nerve system
function is assessed by measuring heart rate variability
[26]. Bone mass density is measured at baseline and after
12 months, to investigate rate of bone loss among women
with climacteric symptoms. Evaluations further include
measurements of serum FSH and estradiol at baseline and
end of intervention, to confirm that the women are post-
menopausal.
Participants are recruited to three centres (Tromsø, Oslo
and Bergen), by the use of newspaper advertisements and
promotion through media coverage. Informed consent is
obtained from all participants before randomisation. See
eligibility criteria in table 1.
Randomization
Participants are stratified by centre and thereafter block
randomised (random block size) to additional acupunc-
ture or no additional acupuncture. Staff at study head-
quarters at University Hospital of North Norway (UNN),
which is not connected with the study, prepared the ran-
domisation database and acts as a central randomisation
service. Each local coordinator (Tromsø, Oslo and Ber-
gen) obtains distance randomisation of included partici-
pants.
Experimental intervention
Traditional acupuncturists, using diagnostic methods
according to the principles of Traditional Chinese Medi-
cine, diagnose TCM syndromes associated with the symp-
toms of menopausal hot flushes. The acupuncturists meet
the criteria for membership in the Norwegian acupunc-
ture society, "Norsk Akupunkturforening" (NAFO), and
have at least five years experience of practice. There are
four practitioners in Oslo, three in Bergen and three in
Tromsø. This will ensure that the study tests the effects of
TCM acupuncture-care, not the individual practitioner.
The Delphi technique [27] has been used to establish a
consensus between acupuncturists regarding the stand-
ardized diagnostic criteria and treatment guidelines, as
previously successfully used for acupuncture treatment of
lateral epicondylitis [28].
After the initial diagnosis, each participant is treated with
points selected according to the syndrome diagnosis. The
acupuncturists are free to add individualised points to
treat other symptoms related to the menopause (i.e. those
included on the WHQ such as depression, anxiety, insom-
nia), but not unrelated symptoms. In addition, acupunc-
turists can use moxibustion (warmed needles) if
indicated. The acupuncture treatment comprises up to 10
treatment sessions over 12 weeks. This period can be
extended for 2 weeks to allow for personal circumstances.
The minimum treatment defined 'per protocol' is 6 ses-
sions.
The acupuncture-care group is free to use any over the
counter (OTC) drugs and self-provided non-pharmaceuti-
cal intervention during the intervention period. In addi-
tion, they can use soy, specific dietary supplements and
herbal medicines.BMC Complementary and Alternative Medicine 2007, 7:6 http://www.biomedcentral.com/1472-6882/7/6
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Control intervention
The control group is free to use any OTC drugs and self-
provided non-pharmaceutical intervention during the
intervention period. In addition, they can use soy, specific
dietary supplements and herbal medicines.
Many possible control interventions were considered and
rejected for a variety of reasons. Standard HRT has been
tested many times and its effect is well known, as is the
effect of placebo HRT [2,10]. Acupuncture is expected to
be somewhat less effective in relieving hot flushes, and in
this study we focus specifically on the increasing number
of women who deliberately are seeking an alternative to
HRT. At present there is no satisfactory placebo for acu-
puncture. Needles inserted into the skin avoiding acu-
puncture points and meridians (sham acupuncture) are
likely to have some effect [29], and the blunt needles
(Streitberger needles) that have been developed are diffi-
cult to use [30]. In addition, acupuncturists are generally
uncomfortable using placebo-needles. This attitude is
likely to influence the interaction between therapist and
study participant and may influence study results. In this
study we want to evaluate acupuncture as it is practised in
Norway.
Adjunctive intervention: self care
All participants are given an information leaflet on availa-
ble self-provided care (e.g. soy, herbs, local oestrogen,
physical activity, relaxation techniques to treat menopau-
sal symptoms), and they are free to use any of these.
The information leaflet is specially prepared by the project
team and is based on an authoritative book [31] and best
current advice [12].
Effect measures
Primary endpoint is mean number of hot flushes per 24
hours measured over a one-week period. The numbers of
hot flushes are recorded in a daily diary, and flushes are
scored by severity on a scale from of zero to ten. The diary
is administered for two weeks during the qualifying
period, and for one week after 4, 8 and 12 weeks of the
intervention period.
Secondary endpoint is the Women's Health Question-
naire (WHQ), a validated, self-administered instrument
containing 36 questions assessing a wide range of physical
and emotional symptoms of women in the postmenopau-
sal period [32]. A Norwegian version is available and has
been validated linguistically. A psychometric validation of
the WHQ will be performed during the study period. The
WHQ is administered at baseline and at 12 weeks.
Baseline assessment includes sociodemographic data col-
lected in a manner parallel to the NOWAC study [33],
medical and gynaecological history, previous experience
with acupuncture, which other self-provided and thera-
pist-provided interventions they have used earlier to
relieve their climacteric complaints, current use of drugs
and dietary supplements, level of physical activity, smok-
ing status and level of alcohol consumption.
At the end of interventions, all participants are asked
which other self-provided and therapist-provided inter-
ventions they have used to relieve their climacteric com-
plaints during the intervention period.
A hot flush diary and the WHQ are administered to partic-
ipants in the acupuncture group at 6 and 12 months after
the baseline evaluation. The follow up-period allows us to
investigate the development of symptoms and the use of
symptom relieving interventions after the intervention
period (natural course of symptoms and choice of treat-
ment).
At each treatment session the acupuncturists ask specifi-
cally about, and record, any adverse events that have
occurred during or after the last treatment, and adverse
event forms are filled in at 4, 8 and 12 weeks. The women
are asked specifically about adverse events in the 8- and
12-weekly diaries.
The excretion of CGRP and NPY in early morning and
evening urine samples are measured with a radioimmu-
noassay method [15], to determine any changes during
the intervention period. The measurements are related to
serum creatinine.
Heart rate variability measurements are done at baseline
and after 12 weeks. After five minutes rest, a ten minutes
registration is done with a Novacor Holter-monitor and
Holtersoft Ultima software.  Figure 1 shows a  flow dia-
gram of the study design, and the data collection schedule
is  detailed in table 2.
Statistical power and sample size
Calculations were made in consultation with a profes-
sional statistician. The sample size was calculated using
NCSS (PASS 2002) programme, using data for hot flush
frequency from many previous trials of HRT, herbs and
acupuncture. With a baseline daily flush rate of 7.0 (SD
3.0), and assuming that the difference of interest is 20 per-
centage points (post-treatment flush rates of 3.5 and 4.9
for acupuncture and no acupuncture groups respectively,
equivalent to reductions of 50% and 30%, and SD 3.5 for
change in flush rate), and employing a two-sided, two-
sample t-test for the changes, 100 women in each group
were needed to identify a 20% difference with a power of
80% and α-value of 0.05. Assuming a total withdrawal
and dropout rate of 30%, we estimated that a total sample
size of 286 women is required.BMC Complementary and Alternative Medicine 2007, 7:6 http://www.biomedcentral.com/1472-6882/7/6
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Power calculations for the sub-study of biological varia-
bles are based on earlier studies of the CGRP excretion in
urine during acupuncture treatment [15]. To identify a
supposed 30% difference in CGRP urine excretion with a
power of 80% and α-value of 0.05, we need 25–30 partic-
ipants in each group. To allow for some measurement
inaccuracies because CGRP and NYP are to be measured
in early morning and evening urine samples, we will use
35 participants in each group.
Data entry is undertaken by the central coordinator, with
checking of random 10% samples by the research fellow.
Data on primary endpoint are entered by a person not
connected to the study team, and who is blinded to treat-
ment allocation.
Data analysis and handling
All analyses are conducted blinded to group allocation.
Missing data are substituted by last value carried forward.
The primary analysis is intention-to-treat, comparing
mean changes from baseline to end of treatment after 12
weeks in the two groups, using a two-sample t-test. In the
presence of meaningful baseline differences, analysis of
covariance will be employed. It is anticipated that the data
will be somewhat right-skewed, therefore analyses will be
checked after appropriate data conversion, and also
checked using non-parametric methods. Secondary analy-
ses will compare the changes at different time points. Sec-
ondary measures will be analysed using appropriate
parametric or non-parametric methods. Subgroup analy-
ses include per-protocol analyses to assess efficacy of acu-
puncture care, and comparison of changes in hot flush
rate among women grouped by TCM syndromes.
The trial headquarters is located at UNN Clinical Research
Centre where they have experience in running multicenter
studies. All data sheets are rendered anonymous by
removing participant names and addresses. The personal
information and the index that links trial numbers with
individual participants is kept under lock and key in the
possession of each local coordinator. Trial number alone
identifies all computerised data. To prevent reporting
bias, all the participant evaluation forms are administered
by the trial headquarters in Tromsø. The participants
return the evaluation forms to the trial headquarters in
Tromsø.
Participants in either study group who choose to use any
therapist-provided care to relieve hot flushes (e.g. mas-
sage, homeopathy or any prescribed medication to relieve
hot flushes such as systemic estrogen or SSRI's from any
source) during the 12 week study period, are followed up
with registration of events and included in the intention-
to-treat analysis.
Data and safety monitoring
A Steering Group retains responsibility for quality control
and meet on a regular basis throughout the study period.
In addition, the Steering Group can be convened as an
emergency in the event of a serious adverse event associ-
ated with the trial to decide on appropriate action to pre-
vent recurrence. Regular meetings will consider any
reported adverse events, protocol violations, the recruit-
ment rate, and any practical issues concerning local coor-
dination, acupuncture practitioners, as well as any issues
raised by participants.
The study is performed according to the Helsinki declara-
tion and Good Clinical Practice requirements [34]. The
study has been approved by the Norwegian Data Inspec-
torate and the Norwegian Biobank Registry, and recom-
mended by the Ethics Committee.
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Table 1: Eligibility criteria
Inclusion criteria
Postmenopausal (>1 year past last menstruation)
Willing to receive acupuncture
Mean value of ≥7 hot flushes/24 hours during a time period of 7 days
Exclusion criteria
Surgical menopause
History of cancer within the past five years
Use of anticoagulant drugs
Heart valve disease
Poorly controlled hypertension
Poorly controlled hypothyroidism
Hyperthyroidism
Poorly controlled diabetes mellitus
Organ transplant
Mental disease
Overt drug or alcohol dependency
Inability to complete study forms
Use of HRT (Wash out period: 8 weeks for systemic and 4 weeks for 
local use)
Use of SSRI (Wash out period: 8 weeks)BMC Complementary and Alternative Medicine 2007, 7:6 http://www.biomedcentral.com/1472-6882/7/6
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Flow diagram of study design Figure 1
Flow diagram of study design.
12 mo: Hot flushes, WHQ 12 mo: Hot flushes, WHQ 
6 mo: Hot flushes, WHQ 
12 wks: Hot flushes, WHQ 
End of study
6 mo: Hot flushes, WHQ
12 wks: Hot flushes, WHQ
End of study
8 wks: Hot flushes, WHQ 
4 wks: Hot flushes, WHQ 
8 wks: Hot flushes, WHQ
4 wks: Hot flushes, WHQ
Self care 
n=143
Acupuncture group 
n= 143 
10 acupunture sessions
n= 286 women randomized 
N=700 (?) women recruited
by media coverage and newspaper ads
Hot flush diary for 2 weeks 
Health related quality of life (WHQ) BMC Complementary and Alternative Medicine 2007, 7:6 http://www.biomedcentral.com/1472-6882/7/6
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Table 2: Data collection schedule
Qualifying period 2 wks Baseline Randomisation End Follow-up
Visit number 1 2 31
Week number ≤-2 0 4 8 12 26 52
Participant provided data
Hot flush diary X X X X X X
WHQ XX X X
EQ-5D X X X X
Sociodemographic variables X
Beck depression inventory1 XX X X
Hopkins symptoms checklist2 X
SF362 X
Lifestyle/physical activity X X X X X X
Medical history X
Use of health care services 3 XX X X X X
Dietary supplements/herbs X X X X X X
OTC-drugs X X X X X X
Prescribed drugs X X X X X X
Side effects XX X
Biological variables 1
Sex hormones, creatinine X X
CGRP, NPY X X
Heart rate variability X X
Bone mass density X X
Qualitative data 2
Acupuncturist provided data X
TCM diagnose X X
Acupoints used X X X X X X X X X X
Side effects X X X X X X X X X
1 Subsample of n = 70 women participating in study of biological variables
2 Subsample of n = 200 women
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